Clinical Trial: Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187778) titled 'Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)' on Sept. 16.

Brief Summary: To learn if belzutifan alone, pembrolizumab alone, or belzutifan and pembrolizumab in combination given before a total or partial nephrectomy (surgery to remove all or part of a kidney) can help to control locally advanced ccRCC.

Study Start Date: Feb. 28, 2026

Study Type: INTERVENTIONAL

Condition: Clear Cell Renal Cell Carcinoma

Intervention: DRUG: Pembrolizumab

Oral administration

DRUG: Belzutifan

Oral administration

Recruitment Status: NOT_YET_RECRU...